Please login to the form below

Not currently logged in
Email:
Password:

Ironwood Pharmaceuticals

This page shows the latest Ironwood Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug. Duzallo will be launched in the US before the end of this year. ... alone - perhaps modest for AZ but significant for Ironwood which made $274m in total revenues last year.

Latest news

  • AZ sells Zurampic rights to Gruenenthal for $230m AZ sells Zurampic rights to Gruenenthal for $230m

    AZ previously sold US rights to Zurampic and the follow-up to Ironwood Pharmaceuticals for $265m plus royalties. ... The drug is approved for use alongside xanthine oxidase (XO) inhibitors such as generic allopurinol or Takeda's Uloric (febuxostat) in

  • AZ adds gout drug Zurampic to asset sale AZ adds gout drug Zurampic to asset sale

    AZ adds gout drug Zurampic to asset sale. Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product. ... The licensing agreement gives Ironwood Pharmaceuticals exclusive US rights to Zurampic (lesinurad), which was approved

  • AZ and Ironwood to file IBS drug linaclotide in China next year AZ and Ironwood to file IBS drug linaclotide in China next year

    AstraZeneca (AZ) and Ironwood Pharmaceuticals say they are on course to submit irritable bowel syndrome treatment linaclotide for approval in China in early 2016. ... Linaclotide is a guanylate cyclase‐ C agonist that is already sold in the US as

  • AstraZeneca signs IBS collaboration with Ironwood in China AstraZeneca signs IBS collaboration with Ironwood in China

    AstraZeneca signs IBS collaboration with Ironwood in China. Deal will also see Ironwood’ s US sales force promote Nexium for gastroesophageal reflux disease. ... AstraZeneca (AZ) has signed a deal worth up to $150m with Ironwood Pharmaceuticals to

  • Almirall's IBS drug Constella backed by CHMP

    The positive opinion for Constella comes after the drug was approved in the US, where it will be sold by originator Ironwood Pharmaceuticals and co-marketing partner Forest Laboratories when it

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    In a "mirror deal" in April this year, AstraZenenca licensed US rights to Zurampic and the fixed dose combination to Ironwood Pharmaceuticals for $100m upfront and up to $165m in further ... collaboration, licence, equity. 73.5. PAION/ Cosmo

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel. ... Meanwhile, Valles-Sukkar arrives

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Vertex poaches new finance chief from Ironwood Pharmaceuticals. Boston-based biotech company appoints Tom Graney. ... Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer.

  • Ironwood Pharmaceuticals appoints chief development officer Ironwood Pharmaceuticals appoints chief development officer

    Ironwood Pharmaceuticals appoints chief development officer. Dr Christopher Wright joins from Axcella Health. ... Ironwood Pharmaceuticals has appointed Dr Christopher Wright as its new senior vice president of global development and chief development

  • Proteostasis Therapeutics strengthens leadership team Proteostasis Therapeutics strengthens leadership team

    James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia. ... Center. Chhabra said: “ Geoffrey's extensive experience leading clinical

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Ironwood appoints Edward Owens to board. He brings experience as portfolio manager of Vanguard Health Care Fund. ... Ironwood Pharmaceuticals has appointed Edwards Owens to the company's board of directors.

More from appointments
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics